434 related articles for article (PubMed ID: 11173809)
1. Activity of moxifloxacin and twelve other antimicrobial agents against 216 clinical isolates of Streptococcus pneumoniae.
Esposito S; Noviello S; Ianniello F
Chemotherapy; 2001; 47(2):90-6. PubMed ID: 11173809
[TBL] [Abstract][Full Text] [Related]
2. Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model.
Esposito S; Noviello S; Ianniello F
J Chemother; 2000 Dec; 12(6):475-81. PubMed ID: 11154028
[TBL] [Abstract][Full Text] [Related]
3. Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin.
Klugman KP; Capper T
J Antimicrob Chemother; 1997 Dec; 40(6):797-802. PubMed ID: 9462430
[TBL] [Abstract][Full Text] [Related]
4. Moxifloxacin: a comparison with other antimicrobial agents of in-vitro activity against Streptococcus pneumoniae.
Reinert RR; Schlaeger JJ; Lütticken R
J Antimicrob Chemother; 1998 Dec; 42(6):803-6. PubMed ID: 10052905
[TBL] [Abstract][Full Text] [Related]
5. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
Hoellman DB; Lin G; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 1999 May; 43(5):645-9. PubMed ID: 10382885
[TBL] [Abstract][Full Text] [Related]
6. Antibiotic susceptibility of clinical isolates of Streptococcus pneumoniae.
Traub WH; Leonhard B
Chemotherapy; 1996; 42(4):240-7. PubMed ID: 8804790
[TBL] [Abstract][Full Text] [Related]
7. Changing trends in antimicrobial susceptibility of Streptococcus pneumoniae isolates in Taiwan, 2006-2007.
Li CF; Liu MF; Shi ZY; Hsueh PR; Liao CH; Jang TN; Tsao SM; Kung HC; Hsu GJ; Cheng YJ; Lin HC; Liu YC; Chuang YC; Wang LS; Chen CM
J Microbiol Immunol Infect; 2012 Aug; 45(4):305-10. PubMed ID: 22608926
[TBL] [Abstract][Full Text] [Related]
8. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC
Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of gemifloxacin against Streptococcus pneumoniae isolates in Germany.
Lemmen S; Al-Lahham A; Lütticken R; Reinert RR
Chemotherapy; 2001; 47(2):104-9. PubMed ID: 11173811
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity and spectrum of sparfloxacin tested against erythromycin-resistant Streptococcus pneumoniae isolates.
Barrett MS; Jones RN
Diagn Microbiol Infect Dis; 1996 Feb; 24(2):113-6. PubMed ID: 9147907
[TBL] [Abstract][Full Text] [Related]
11. Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral beta-lactams.
Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1997 Dec; 41(12):2786-9. PubMed ID: 9420061
[TBL] [Abstract][Full Text] [Related]
12. Comparative in-vitro activity of moxifloxacin, penicillin, ceftriaxone and ciprofloxacin against pneumococci isolated from meningitis.
Tarasi A; Capone A; Tarasi D; Cassone M; Bianco G; Venditti M
J Antimicrob Chemother; 1999 Jun; 43(6):833-5. PubMed ID: 10404324
[TBL] [Abstract][Full Text] [Related]
13. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.
Spangler SK; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1992 Apr; 36(4):856-9. PubMed ID: 1323956
[TBL] [Abstract][Full Text] [Related]
14. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1994 Sep; 38(9):2065-72. PubMed ID: 7811020
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.
Saravolatz L; Manzor O; Check C; Pawlak J; Belian B
J Antimicrob Chemother; 2001 Jun; 47(6):875-7. PubMed ID: 11389122
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae.
Frédénucci I; Chomarat M; Bercion R; Carricajo A; Celard M; Croizé J; Delubac F; Fèvre D; Fuhrmann C; Helfre M; Letouzey MN; Lelièvre H; Mandjee A; Marthelet P; Meley R; Perrier-Gros-Claude JD; Ros A; Roure C; Smati S; Thierry J; Tous J
Clin Microbiol Infect; 2002 Oct; 8(10):680-3. PubMed ID: 12390289
[TBL] [Abstract][Full Text] [Related]
17. Activity of oral agents against pediatric isolates of Streptococcus pneumoniae.
Black J; Moland ES; Chartrand SA; Thomson KS
Diagn Microbiol Infect Dis; 2001 Mar; 39(3):195-7. PubMed ID: 11337189
[TBL] [Abstract][Full Text] [Related]
18. [In vitro activity of six fluoroquinolones and penicillin against 101 viridans group streptococci characterized by their susceptibility to erythromycin].
Rodríguez-Avial I; Rodríguez-Avial C; Picazo JJ
Rev Esp Quimioter; 2001 Dec; 14(4):364-8. PubMed ID: 11856983
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility of penicillin-resistant and penicillin-susceptible Streptococcus pneumoniae to newer antimicrobial agents.
Rubio MC; Goñi P; Vergara Y; Seral C; García C; Gómez-Lus P; Gómez-Lus R
J Chemother; 1999 Jun; 11(3):191-4. PubMed ID: 10435680
[TBL] [Abstract][Full Text] [Related]
20. [National multicenter study of the in vitro activity of moxifloxacin against respiratory tract pathogens. Spanish Study Group on Moxifloxacin].
Loza E; Morosini M; Negri MC; Almaraz F; Cantón R; Baquero F
Rev Esp Quimioter; 2000 Mar; 13(1):37-43. PubMed ID: 10855023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
